| 公開(公告)號 | CN1305897C |
| 公開(公告)日 | 2007.03.21 |
| 申請(專利)號 | CN99103987.4 |
| 申請日期 | 1999.03.15 |
| 專利名稱 | 新肽化合物和其制備方法及含有它們的藥物組合物 |
| 主分類號 | C07K14/00(2006.01)I |
| 分類號 | C07K14/00(2006.01)I;C07K1/06(2006.01)I;A61K38/16(2006.01)I;A61P3/10(2006.01)I |
| 分案原申請?zhí)? | |
| 優(yōu)先權(quán) | 1998.4.10 FR 9804559 |
| 申請(專利權(quán))人 | 瑟維爾實驗室 |
| 發(fā)明(設(shè)計)人 | B·卡拉斯;G·格拉希;A·查瓦尼尤;C·薩拉斯特德門希里;P·里納德;B·普費夫;D·馬尼徹茲 |
| 地址 | 法國庫伯瓦 |
| 頒證日 | |
| 國際申請 | |
| 進入國家日期 | |
| 專利代理機構(gòu) | 中國國際貿(mào)易促進委員會專利商標事務(wù)所 |
| 代理人 | 周中琦 |
| 國省代碼 | 法國;FR |
| 主權(quán)項 | 肽類化合物，其是 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-(D)-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·Trp-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-(D)-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·Trp-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·His-Ala-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Val-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·His-Ala-His-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Val-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·His-Ala-(D)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-(D)-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Leu-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Val-Glu-Gly-Thr-phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·Afp-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Ser-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Lys-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·Phe-(D)-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Lys-Tyr-Leu-Glu-Gly-Gln-Ala-Val-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·Phe-(D)-Ala-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Val-(D)-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Leu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Met-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Trp-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Ile-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Val-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-His-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Asp-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Leu-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Val-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Tyr-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Arg-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Glu-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·Phe-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-NH2 ·His-Ala-Lys-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-NH2 ·His-Ala-Met-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- |
| 摘要 | 具有化學(xué)式(Ⅰ)的肽化合物：Z1-X1-X2-X3-Gly-Thr-Phe-Thr-Ser-X4-X5-Ser-X6-X7-X8-Glu-Gly-Gln-Ala-X9-Lys-X10-X11-X12-Ala-X13-X14-Val-Lys-Gly-X15-Gly-Z2 （Ⅰ)其中：Z1，末端氨基取代基，代表被選擇性取代的氫原子或烷基或�；蚍剪驶�、雜烷羰基、芳烷羰基、雜芳羰基、芳氧羰基、芳烷氧羰基或烷氧羰基，Z2，末端羰基取代基，代表羥基、烷氧基或選擇性取代的氨基。X1至X14，分別代表如說明書中所定義的，具D或L構(gòu)型的氨基酸殘基。X15代表鍵或精氨酸殘基(Arg)；及藥物。 |
| 國際公布 |
